title: Potential harmful correlation between homocysteine and low-density lipoprotein cholesterol in patients with hypothyroidism.
abstract: OBJECTIVE
  Hypothyroidism (HO) can induce metabolic dysfunctions related to insulin resistance and dyslipidemia. Our previous studies showed that homocysteine (Hcy) impaired the coronary endothelial function and that Hcy can promote chemokine expression and insulin resistance (IR) by inducing endoplasmic reticulum stress in human adipose tissue and hypothyroid patients. The aim of this study was to investigate the potential harmful correlation between plasma Hcy and low-density lipoprotein cholesterol (LDL-C) in patients with HO.
  
  
  METHODS
  A total of 286 subjects were enrolled. All subjects were divided into the following 3 groups: HO group, subclinical hypothyroidism (SHO) group, and control group. Statistical analyses were carried out to evaluate the correlation between the plasma levels of Hcy and LDL-C in HO patients. The changes in the plasma Hcy levels and other metabolic parameters were measured before and after levothyroxine (L-T4) treatment. The relationship between the changes in the plasma Hcy level and the LDL-C level was also evaluated after L-T4 treatment.
  
  
  RESULTS
  In the patients with HO, both the plasma Hcy and LDL-C levels were significantly higher than those of the controls. The plasma levels of Hcy were positively correlated with the LDL-C level in the HO group. L-T4 treatment resulted in a significant decrease in the BMI, total cholesterol (TC), LDL-C, triglycerides (TG), apolipoprotein B (ApoB), and Hcy levels. Moreover, the decrease in Hcy (ΔHcy) was positively correlated with decreased LDL-C (ΔLDL-C) levels after L-T4 treatment in HO patients.
  
  
  CONCLUSIONS
  Our results suggest that the increased Hcy level was positively correlated with the LDL-C in the HO group. A potential harmful interaction may exist between Hcy and LDL-C under the HO condition. In addition to reducing the plasma levels of Hcy, L-T4 treatment exerts beneficial effects on patients with HO by improving dyslipidemia, including a decrease in the LDL-C level.
authors.affiliation: Department of Endocrinology, Beijing Chao-yang Hospital, Capital Medical University, Beijing, China.
authors.forename: Xuejie
authors.initials: X
authors.lastname: Dong
authors.forename: Zhi
authors.initials: Z
authors.lastname: Yao
authors.forename: Yanjin
authors.initials: Y
authors.lastname: Hu
authors.forename: Ning
authors.initials: N
authors.lastname: Yang
authors.forename: Xia
authors.initials: X
authors.lastname: Gao
authors.forename: Yuan
authors.initials: Y
authors.lastname: Xu
authors.forename: Guang
authors.initials: G
authors.lastname: Wang
mesh_terms: D000328:Adult; D008078:Cholesterol, LDL / Q000097:blood*; D015331:Cohort Studies; D005260:Female; D006710:Homocysteine / Q000097:blood*; D006801:Humans; D007037:Hypothyroidism / Q000097:blood* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D012016:Reference Values; D013223:Statistics as Topic; D013960:Thyroid Function Tests; D013974:Thyroxine / Q000627:therapeutic use
chemical_list: D008078:Cholesterol, LDL; D006710:Homocysteine; D013974:Thyroxine